medigraphic.com

2002, Número 1

<< Anterior Siguiente >>

Rev Mex Med Urg 2002; 1 (1)


Consenso Nacional del Manejo Integral de la Hipertensión Portal Hemorrágica en Urgencias

Velasco DV, Vázquez DIM, Loria CJ, Gutiérrez LR, Gómez AV, Hernández HJ, Pedroza UE, Valladares AMA, Garduño ESA, Ramírez SFF, Ortiz MC, Martínez CA

Idioma: Español
Referencias bibliográficas: 57
Paginas: 12-23
Archivo PDF: 89.95 Kb.


FRAGMENTO

Tomando como documento base las conclusiones emanadas del Primer Consenso Nacional del Manejo Integral de la Hipertensión Portal Hemorrágica, que fue realizado en noviembre de 1997 en Ixtapa, Zihuatanejo; en esta ocasión, el día 3 de noviembre del 2001 se reunió un grupo de reconocidos médicos mexicanos pertenecientes a La Sociedad Mexicana de Medicina de Emergencia. Esta Sociedad constituye el órgano encargado de difundir los conceptos más relevantes y de mayor actualidad con relación a la medicina de urgencia, como en este Consenso, cuyo objetivo primordial fue el de unificar criterios y, de esta manera, establecer lineamientos y directrices para el manejo integral de la hipertensión portal hemorrágica dentro de los Servicios de Urgencias. En este sentido, el sangrado del tubo digestivo debido a este síndrome es considerado por estos expertos como una urgencia extrema, toda vez que invariablemente conlleva un riesgo vital para los pacientes que lo presentan y que, prácticamente en el 100% de los casos son atendidos en los Servicios de Urgencias de los diferentes hospitales de nuestro país.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lebrec D, de Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980;79:1139-44.

  2. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.

  3. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994; 64: 65-107.

  4. Lebrec D, Nouel O, Corbic M, Benhamou JP. Propanolol: a medical treatment for portal hypertension. Lancet 1980;I:121-4.

  5. Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou J.P. Comparison of the effects of a cardioselective and a nonselective [beta]-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982;2:528-31.

  6. Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propanolol in prevention of variceal haemorrhage. Lancet 1990;336:153-6.

  7. Brenner DA, Alcorn JM. Therapy for hepatic fibrosis. Semin Liver Dis 1990;10:75-83.

  8. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. J Hepatol 1995;22:370-6.

  9. Zhang B, Calmus Y, Weng L, Sogni P, Lotersztajn S, Houssin D, et al. Endothelin-1 induces liver vasoconstriction through ETA and ETB receptors. J Hepatol 1997;26:1104-10.

  10. Moreau R, Lee SS, Hadengue A, Braillon A, Lebrec D. Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987;7:149-54.

  11. Roulot D, Moreau R, Gaudin C, Bacq Y, Braillon A, Hadengue A, et al. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites. Gastroenterology 1992,102:1309-18.

  12. Albillos A, Banares R, Barrios C, Clemente C, Rossi I, Escartin P, et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology 1992;102:248-54.

  13. Moreau R, Komeichi H, Kirstetter P, Ohsuga M, Cailmail S, Lebrec D. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology 1994;106:1016-23.

  14. Moreau R, Komeichi H, Cailmail S, Lebrec D. Blockade of ATP-sensitive K+ channels by glibenclamide reduces portal pressure and hyperkinetic circulation in portal hypertensive rats. J Hepatol 1992;16:215-8.

  15. Piczueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:184-90.

  16. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-8.

  17. Pilette C, Kirstetter P, Sogni P, Cailmail S, Moreau R, Lebrec D. The effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertensive rats. J Hepatol Gastroenterol 1995;11:1-6.

  18. Sogni P, Yang S, Pilette C, Moreau R, Gadano A, Avenard G, et al. Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats. Eur J Pharmacol 1998.

  19. Midgley S, Grant IS, Haynes WG, Webb DJ. Nitric oxide in liver failure. Lancet 1991;338:1590.

  20. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 1993;18:621-7.

  21. Wu Y, Cartland Burns R, Sitzmann JV. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension. Hepatology 1993;18:1416-21.

  22. Moreau R, Cailmail S, Rona JP, Lahaye P, Lebrec D. The calcium channel activator, Bay K 8644, increases cytosolic free Ca2+ concentrations in arterial myocytes and reduces hyperdynamic circulation in portal hypertensive rats. Hepatology 1995;22:168ª.

  23. Jones AL, Hayes PC. Organic nitrates in portal hypertension. Am J Gastroenterol 1994;89:7-14.

  24. Moreau R, Lebrec D. Nitrovasodilators and portal hypertension. J Hepatol 1990;10:263-7.

  25. Forrest EH, Jalan R, Redhead DN, Hayes PC. Differing actions of the acute administration of propanolol and isosorbide-5-mononitrate on the portal circulation. Aliment Pharmacol Ther 1996;10:795-800.

  26. Poo JL, Braillon A, Hadengue A, Gaudin C, Lebrec D. Hemodynamic effects of terbutaline, a [beta]2-adrenoceptor agonist, in conscious rats with secondary biliary cirrhosis. Hepatology 1992;15:459-63.

  27. Lebrec D, Cailmail S, Moreau R, Gadano A, Clozel M. Beneficial hemodynamic effects of bosentan, an ETA and ETB receptor antagonist of endothelin in portal hypertension. Hepatology 1996;24: 316A.

  28. Reichen J, Sägesser S. Endothelin inhibits microvascular exchange and endothelin antagonists improve microvascular exchange more in cirrhotic than in normal rat liver. Hepatology 1994;20:202A.

  29. Reichen J, Sägesser S. Endothelin inhibits microvascular exchange and endothelin antagonists improve microvascular exchange more in cirrhotic than in normal rat liver. Hepatology 1994;20:202A.

  30. Albillos A, Lledo JL, Rossi I, Pérez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257-65.

  31. Svoboda P, Ochmann J, Kantorova I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. Hepatogastroenterology 1992;39:549-52.

  32. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J Gastroenterol Hepatol 1995;10: 256-60.

  33. Huang YT, Wang GF, Chen CF, Chen CC, Hong CY, Yang MCM. Fructus aurantii reduced portal pressure in portal hypertensive rats. Life Sci 1995;57:2011-20.

  34. Dagenais M, Pomier-Layrargues G, Rocheleau B, Giroux L, Huet PM. Systemic and splanchnic haemodynamic effects of pentifylline in rats with portal hypertension. Clin Sci 1992;83:41-5.

  35. Soupison T, Yang S, Bernard C, Moreau R, Kirstetter P, D’Almeida M, et al. Acute haemodynamic responses and inhibition of tumour necrosis factor-[alpha] by pentoxifylline in rats with cirrhosis. Clin Sci 1996;91:29-33.

  36. Sanchez S, Albornoz L, Bandi JC, Gerona S, Mastai R. Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis. Eur J Gastroenterol Hepatol 1997;9:27-31.

  37. Oberti F, Pilette C, Rifflet H, Maïga MY, Moreau A, Gallois Y, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997;26:1363-71.

  38. Grangé JD, Jaillon P, Noblinski B, Faucherre V, Ballet F, Vasmant D, et al. La pentoxifylline: un traitement potentiel des cirrhoses avec hypertension portale. Gastroenterol Clin Biol 1987;11:161A.

  39. Cereda JM, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol 1989;9:246-51.

  40. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.

  41. Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Ginés P, Pizcueta P, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19:1095-9.

  42. Koda M, Murawaki Y, Kawasaki H, Ikawa S. Effects of canrenoate potassium, an aldosterone antagonist, on portal hemodynamics in patients with compensated liver cirrhosis. Hepatogastroenterology 1996;43:887-92.

  43. Nevens F, Lijnen P, VanVilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996:23:1047-52.

  44. Van De Casteele M, Van Roey G, Nevens F, Fevery J. Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats. Hepatology 1996;24:1492-516.

  45. Lebrec D. Portal hypertension: serotonin and pathogenesis. Cardiovasc Drugs Ther 1990;4:31-3.

  46. Beaudry P, Hadengue A, Callebert J, Gaudin C, Soliman H, Moreau R, et al. Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology 1994;20:800-3.

  47. Hadengue A, Lee SS, Moreau R, Braillon A, Lebrec D. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension. Hepatology 1987;7:644-7.

  48. Vorobioff J, Garcia-Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, et al. Long-term hemodynamic effects of ketanserin, a 5-hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989;8:88-91.

  49. Mastai R, Giroux L, Semret M, Huet PM. Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats. Gastroenterology 1990;98:141-5.

  50. Nevens F, Pizcueta M.P, Fernandez M, Bosch J, Rodés J. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats. Hepatology 1991;14:1174-8.

  51. Yang NC, Pang PKT, Lay CS, Wu SL, Jan KM, Tsai YT, et al. Effect of parathyroid hormone on portal pressure in portal hypertensive rats. Liver 1990;10:11-6.

  52. Chao TW, Yu PC, Kuo JS, Pang PKT, Yang MCM. Responsiveness to synthetic parathyroid hormone in the portal vein of portal hypertensive rats. J Hepatol 1992;16:326-31.

  53. Sekiyama T, Gaudin C, Roulot D, Lebrec D, Braquet P, Braillon A. Evidence for platelet-activating factor as a mediator for hyperdynamic circulation in conscious cirrhotic rats. In: Braquet P, editor. Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives. Barcelona. Prous Sciences Publisher; 1989: 313-9.

  54. Lee FY, Tsai YT, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic effects of a combination of vasopressin and ketanserin in patients with hepatitis B-related cirrhosis. J Hepatol 1992;15:54-8.

  55. Lebrec D, Moreau R, Cailmail S, Sogni P, Oberti F, Hadengue A. Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propanolol. J Hepatol 1993;17:102-7.

  56. Moreau R, Cailmail S, Gadano A, Valla D, Lebrec D. Haemodynamic effects of octreotide in portal hypertensive rats receiving propanolol. Aliment Pharmacol Ther 1997;11:775-9.

  57. Vachiery F, Moreau R, Gadano A, Yang S, Sogni P, Hadengue A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective [beta]-blocker. Dig Dis Sci 1996;41:1722-6.




2020     |     www.medigraphic.com